Piper Sandler Maintains Overweight on Black Diamond Therapeutic, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Joseph Catanzaro has maintained an Overweight rating on Black Diamond Therapeutic (NASDAQ:BDTX) and raised the price target from $12 to $15.
September 23, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has maintained an Overweight rating on Black Diamond Therapeutic and increased the price target from $12 to $15, indicating a positive outlook.
The increase in price target from $12 to $15 by Piper Sandler suggests a positive outlook for Black Diamond Therapeutic, likely leading to a short-term increase in stock price. The Overweight rating further supports this positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100